Revenue (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of revenue disaggregated by Group, end customer geographical location and timing of recognition

The following table presents the Company’s revenue by end customer geography for the three months ended March 31 (in millions):


	2025		2024
United States	$	217.4	$	194.8
Germany		61.1		66.8
Rest of Europe		224.1		178.1
China		101.2		115.7
Rest of Asia Pacific		131.4		107.0
Other		66.2		59.3
Total revenue	$	801.4	$	721.7

The following table presents revenue for the Company recognized at a point in time versus over time for the three months ended March 31 (in millions):


	2025		2024
Revenue recognized at a point in time	$	678.7	$	608.5
Revenue recognized over time		122.7		113.2
Total revenue	$	801.4	$	721.7

Schedule of contract balances associated with revenue

the three months ended March 31, 2025 and the year ended December 31, 2024 the following balances were associated with revenue (in millions):


	March 31, 2025		December 31, 2024
Contract assets	$	109.1	$	105.2
Contract liabilities (a)		575.9		538.2
Remaining performance obligations (b)	$	2,072.0	$	2,090.4

Approximately $143.0 million of the contract liability balance on December 31, 2024, was recognized as revenue during the three months ended March 31, 2025.

Bruker’s mix of remaining performance obligations, or backlog, consists of firm orders under non-cancelable purchase orders received from customers and the timing of revenue recognition can vary significantly due to a variety of factors. Bruker manufactures innovative scientific instruments and diagnostic solutions which can result in varying production and installation timing due to components, customization, manufacturing, assembly, testing processes, and customer site availability or readiness. Bruker’s expected completion of performance obligation can vary from year to year based on these and other factors. As a result, backlog on any particular date can be indicative of Bruker’s short-term revenue performance but is not necessarily a reliable indicator of long-term revenue performance. The Company will recognize revenues for these performance obligations as they are satisfied, the majority of which is expected to occur within the next twelve months.